Mast Therapeutics, Inc. (MSTX)

[Digger 2-0]

The Company will make the $10 million prepayment on its debt facility triggered by the recently announced results of its Phase 3 study of vepoloxamer in early October 2016. After that prepayment, the principal amount of the Company's debt will be approximately $3.5 million, which is scheduled to be repaid in equal monthly installments of principal and interest through January 1, 2019.

After paying the 10 million, the debt of the companie is only 3.5 million.
They have 20 million in cash (pps 0.12) and they have her pipeline!